Valneva, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Damien Choplain from Stifel Nicolaus maintained a Buy rating on the stock and has a €9.50 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Damien Choplain has given his Buy rating due to a combination of factors that highlight Valneva’s promising future prospects. The company’s Lyme disease vaccine candidate, VLA15, is progressing well with a Phase 3 readout expected in the first half of 2026. This development is crucial as it could lead to regulatory submission and potential approval by 2027, positioning the vaccine for a commercial launch before the 2028 tick season. Valneva’s collaboration with Pfizer, which is leading the Phase 3 program, further strengthens its position, with Valneva set to earn significant royalties and milestone payments upon commercialization.
Additionally, Valneva’s financial health appears robust, with a cash position of €161 million as of mid-2025, which is expected to support the company through the anticipated launch of VLA15. The firm is projected to achieve profitability from 2027 onwards, driven by the approval and recurring revenues from VLA15. Despite challenges with other products, such as the suspension of the US license for Ixchiq, Valneva’s overall revenue growth and strategic financial management contribute to its attractive risk/reward profile, making it a compelling investment opportunity in the European biotech sector.
In another report released on November 4, Kepler Capital also maintained a Buy rating on the stock with a €7.70 price target.